Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future.
نویسندگان
چکیده
The article by Curti and colleagues highlights the potential of natural killer (NK) cell-based adoptive cellular immunotherapy in oncology, currently boosted by advances in the knowledge on NK cell biology and in theirex vivoGMP manipulation. Several issues deserve attention to fully achieve the translation of these advances to the clinic.
منابع مشابه
KIR2DS3 is Associated with Protection against Acute Myeloid Leukemia
Background: Interaction between killer cell immunoglobulin-like receptors (KIR) and human leukocyte antigen (HLA) class I molecules is important for regulation of natural killer (NK) cell function. Objective: The aim of this study was to investigate the impact of compound KIR-HLA genotype on susceptibility to acute leukemia. Methods: Cohorts of Iranian patients with acute myeloid leukemia (AML;...
متن کاملCAR-NK Cells: A Systematic Review of Emerging Alternative on Immunotherapy Against Leukemia
Background: Cancer is a public health emergency. It has a high mortality rate despite numerous studies on pharmaceutical therapies. Chimeric antigen receptor-natural killer (CAR-NK) cells are promising immunotherapy that could be used to treat cancer, especially leukemia. However, the evidence is still unclear. Thus, this systematic review aims to summarize the evidence regarding the use of CAR...
متن کاملAlloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive Immunotherapy
Natural killer (NK) cells express activating and inhibitory receptors, which recognize MHC class-I alleles, termed "Killer cell Immunoglobulin-like Receptors" (KIRs). Preclinical and clinical data from haploidentical T-cell-depleted stem cell transplantation have demonstrated that alloreactive KIR-L mismatched NK cells play a major role as effectors against acute myeloid leukemia (AML). Outside...
متن کاملRole of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.
In a phase IV trial, 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin 2 (IL-2) for 18 months to prevent leukemic relapse. During cycles, the treatment resulted in expansion of CD56(bright) (CD3(-)/16(-)/56(bright)) and CD16(+) (CD3(-)/16(+)/5...
متن کاملTargeting the Minimal Residual Disease in Acute Myeloid Leukemia: The Role of Adoptive Immunotherapy with Natural Killer Cells and Antigen-Specific Vaccination
Acute myeloid leukemia (AML) is a neoplastic disorder characterized by the clonal expansion of non-lymphoid hematopoietic progenitor cells with failure of normal hematopoiesis. Several biological and clinical parameters have been identified at diagnosis to classify different AML subtypes with different prognosis. In this view, genetic abnormalities confer the most important prognostic informati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical cancer research : an official journal of the American Association for Cancer Research
دوره 22 8 شماره
صفحات -
تاریخ انتشار 2016